Biotech RadarJobs updated

COMPANY

Vima Therapeutics

HQ: Boston, MA source · vimatx.com ↗ · New England

Clinical Phase 2

Keywords: dystonia Isolated/Primary Dystonia That Affects More Than One Region of the Body VIM0423

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$100.0MRaised (2 yrs)3Trials (company is sponsor)

Raises and deals from press releases

Raises announced in these releases: $40M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Raise Private equity round — Series A: $100M (total, as published), announced Mar 11, 2026. Source: company release on GlobeNewswire. source ↗
  2. Raise Series A · $40M source ↗
  3. Trial start Phase 2: A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia source ↗
  4. Trial start —: An Observational Study of Individuals With Isolated Dystonia source ↗
  5. Trial start Phase 2: A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $100.0M. Last 2 years.

Clinical trials (lead sponsor) 3

RecordTitlePhaseStatusStartPrimary completion
NCT07111663An Observational Study of Individuals With Isolated DystoniaNot listedActive, not recruitingJun 17, 20252026-10 (estimated)
NCT07304089A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated DystoniaPhase 2RecruitingFeb 5, 20262027-03 (estimated)
NCT07804615A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic TherapyPhase 2Recruiting2026-092027-06 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback